Community Outreach and Engagement

项目摘要/摘要 肯塔基大学(英国)马基癌症中心(MCC)涵盖了整个英联邦 肯塔基州作为它的集水区。尽管最近取得了显著的进展，但肯塔基州的全部位癌症发病率最高 在美国，发病率和死亡率在很大程度上是由社会经济、地理和种族/民族不平等推动的。 拥有47年历史的MCC社区外联和接洽(COE)的目标是参与 社区、从业者和研究人员开展互利合作，以促进卫生公平和 减轻癌症负担。MCC的长期COE计划包括基于地区的社区 外展、该州癌症联盟和政策努力的管理，以及MCC附属网络 (McCan)，MCC的创新临床推广计划，与19家社区(非英国)医院合作 州政府。自2018年以来，MCC进行了战略投资，以增强COE优势，进一步融合 研究和癌症控制。COE之前的需求评估影响了FY19-23财年MCC研究 优先事项。主要成就包括进行2021年肯塔基州癌症需求评估(KY CNA)， 启动新的研究参与计划(例如，社区影响大使作为研究计划 联络、研究倡导计划、临床试验转诊大使、内部COE资金)和癌症 控制范围广泛的活动(例如，培训/技术援助、政策变化、个人教育、 促进服务的访问)。在现有努力和FY24-28财年MCC研究优先事项的基础上，COE 具体目标是：1)监测肯塔基州的癌症负担和差距，并确定社区驱动的 优先事项。除了监测癌症负担和差异并在2026年进行下一次KY CNA外， 每年，COE都会针对特定人群进行重点需求评估，以解决数据差距和 在2021年KY CNA中发现的差距。2)促进有影响力的研究，以响应社区需求和 促进公平。COE将扩展研究倡导计划，为基础和 临床研究人员和“快速反馈会议”。COE将增加两项新策略以促进临床试验 参与：提供适合文化的患者和社区教育，包括证词视频， 并通过协商和多样化，协助优先考虑代表不足的少数群体应计利润的研究 研究倡导者的反馈。3)传播和实施可持续的循证准则和做法 和政策。COE目前正在使用2021年KY CNA来指导该州新五年计划的发展 癌症行动计划。Next CoE将评估其社区癌症控制计划组合，以战略性地 根据新的州计划重新调整它们，以解决差距、利用合作机会并最大限度地发挥影响。 影响：COE在协同MCC研究和癌症控制工作方面取得了重要进展 全州范围内的合作伙伴，并为改善结肠癌和肺癌的人群水平做出了重大贡献 筛查和结果、吸烟和接种HPV疫苗。COE准备进一步加速MCC的影响。

PROJECT SUMMARY/ABSTRACT The University of Kentucky (UK) Markey Cancer Center (MCC) embraces the entire Commonwealth of Kentucky as its catchment area. Despite notable recent advances, Kentucky has the highest all-site cancer incidence and mortality in the U.S., driven largely by socioeconomic, geographic and racial/ethnic inequities. With a 47-year history, the goal of MCC Community Outreach and Engagement (COE) is to engage communities, practitioners and researchers in mutually beneficial collaborations to accelerate health equity and reduce the burden of cancer. MCC’s long-standing COE programs include regionally-based community outreach, management of the state’s cancer coalition and policy efforts, and the MCC Affiliate Network (MCCAN), MCC’s innovative clinical outreach program with 19 community-based (non-UK) hospitals across the state. Since 2018, MCC made strategic investments to enhance COE strengths and further integrate research and cancer control. COE’s previous needs assessment shaped the FY19-23 MCC Research Priorities. Key accomplishments include conducting the 2021 Kentucky Cancer Needs Assessment (KY CNA), launching new research engagement initiatives (e.g., Community Impact Ambassadors as Research Program liaisons, Research Advocacy Program, Clinical Trial Referral Ambassadors, internal COE funding) and cancer control activities with extensive reach (e.g., training/technical assistance, policy changes, individual education, facilitating access to services). Building on existing efforts and FY24-28 MCC Research Priorities, COE Specific Aims are to: 1) Monitor cancer burden and disparities in Kentucky and identify community-driven priorities. In addition to monitoring cancer burden and disparities and conducting the next KY CNA in 2026, each year COE will carry out a focused needs assessment on a specific population to address data gaps and disparities identified in the 2021 KY CNA. 2) Foster impactful research that responds to community needs and promotes equity. COE will expand the Research Advocacy Program with a training module for basic and clinical researchers and “Rapid Feedback Sessions.” COE will add two new strategies to facilitate clinical trial participation: providing culturally appropriate patient and community education, including testimonial videos, and assisting studies prioritized for underrepresented minority accruals through consultations and diverse research advocate feedback. 3) Disseminate and implement sustainable evidence-based guidelines, practices and policies. COE is currently using the 2021 KY CNA to guide development of the state’s new five-year Cancer Action Plan. Next COE will assess its portfolio of community cancer control programs to strategically realign them with the new state plan to address gaps, leverage partnership opportunities and maximize impact. IMPACT: COE has made important advances in synergizing MCC research and cancer control efforts with statewide partners and significant contributions to population-level improvements in colon and lung cancer screening and outcomes, smoking and HPV vaccination. COE is poised to further accelerate MCC impact.